Incyte Corporation (INCY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2,667 | 2,986 | 3,395 | 3,696 | 4,241 | 5,141 | 5,820 | 5,937 |
| Operating profit | $m | 1,343 | 1,837 | ||||||
| Net profit | $m | -296 | 949 | 341 | 598 | 33 | 1,287 | 1,612 | 713 |
| EPS reported | $ | 6.41 | 7.85 | ||||||
| Operating cashflow per share | $ | 7.24 | 9.88 | ||||||
| Capex per share | $ | 0.30 | 0.30 | ||||||
| FCF per share | $ | 6.94 | 9.58 | ||||||
| Free cash flow | $m | 1,355 | 1,920 | ||||||
| Net debt | $m | -3,556 | -4,530 | ||||||
| Book value equity | $m | 5,167 | 6,344 | ||||||
| Book value per share | $ | 25.75 | 30.47 | ||||||
| Number of shares | m | 200.7 | 208.22 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 15.41 | 15.78 | ||||||
| P/B LTM | x | 3.73 | 3.04 | ||||||
| P/S LTM | x | 3.75 | 3.31 | ||||||
| P/FCF LTM | x | 14.23 | 10.04 | ||||||
| EV/EBITDA LTM | x | 9.23 | 7.96 | ||||||
| EV/Sales LTM | x | 3.16 | 3.51 | ||||||
| Earnings Yield LTM | % | +6.49% | +6.34% | ||||||
| FCF Yield | % | +7.03% | +9.96% | ||||||
| Quality | |||||||||
| ROE | % | +24.90% | +29.70% | ||||||
| ROIC | % | +20.58% | +24.59% | ||||||
| Operating margin | % | +26.12% | +31.57% | ||||||
| Gross margin | % | +92.76% | +92.62% | ||||||
| FCF/Sales | % | +26.35% | +33.00% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +21.22% | +37.21% | ||||||
| Net Income Growth YoY | % | +3845.0% | +4843.7% | ||||||
| FCF Growth | % | +443.87% | +671.04% | ||||||
| Operating Profit Growth | % | +1225.6% | +1713.9% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 19.51 | 50.19 | ||||||
| Net Debt/EBITDA | x | -1.72 | -1.93 | ||||||
| EBIT/Net interest | x | 553.04 | 790.59 | ||||||
| Net debt/market cap | % | +0.13% | 0.00% | ||||||
| Net debt/Equity | x | -0.69 | -0.71 | ||||||
| Gross debt/equity | x | 0.01 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free